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Abstract
Lung cancer is the most frequently fatal cancer, with poor
survival once the disease is advanced. Annual low-dose com-
puted tomography has shown a survival benefit in screening
individuals at high risk for lung cancer. Based on the available
evidence, the European Society of Radiology and the
European Respiratory Society recommend lung cancer
screening in comprehensive, quality-assured, longitudinal
programmes within a clinical trial or in routine clinical prac-
tice at certified multidisciplinary medical centres. Minimum
requirements include: standardised operating procedures for
low-dose image acquisition, computer-assisted nodule evalu-
ation, and positive screening results and their management;
inclusion/exclusion criteria; expectation management; and
smoking cessation programmes. Further refinements are rec-
ommended to increase quality, outcome and cost-
effectiveness of lung cancer screening: inclusion of risk
models, reduction of effective radiation dose, computer-
assisted volumetric measurements and assessment of comor-
bidities (chronic obstructive pulmonary disease and vascular
calcification). All these requirements should be adjusted to the
regional infrastructure and healthcare system, in order to ex-
actly define eligibility using a riskmodel, nodule management
and a quality assurance plan. The establishment of a central
registry, including a biobank and an image bank, and prefera-
bly on a European level, is strongly encouraged.
Key points
• Lung cancer screening using low dose computed tomogra-
phy reduces mortality.
• Leading US medical societies recommend large scale
screening for high-risk individuals.
• There are no lung cancer screening recommendations or
reimbursed screening programmes in Europe as of yet.
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• The European Society of Radiology and the European
Respiratory Society recommend lung cancer screening with-
in a clinical trial or in routine clinical practice at certified
multidisciplinary medical centres.
• High risk, eligible individuals should be enrolled in compre-
hensive, quality-controlled longitudinal programmes.
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Abbreviations and acronyms
AATS American Association for Thoracic Surgery
ACCP American College of Chest Physicians
ACS American Cancer Society
ALA American Lung Association
ASCO American Society of Clinical Oncology
CTDIvol Volume CT dose index
COPD Chronic obstructive pulmonary disease
CXR Chest X-Ray
DANTE Detection and Screening of Early Lung Cancer
by Novel Imaging Technology and Molecular
Essays
DLST Danish Lung Screening Trial
IASLC International Association for the Study of Lung
Cancer
ITALUNG Italian lung study
LDCT Low-dose computed tomography
LLP Liverpool Lung Project
LUSI German Lung Screening and Intervention trial
mAs Milliampere-seconds
MILD Multicentric Italian Lung Detection
mSv Millisievert
mGy Milligray
NCCN National Comprehensive Cancer Network
NELSON NEderlands-Leuvens Screening ONderzoek
NLST National Lung Screening Trial
PLCO Prostate Lung, Colorectal, and Ovarian
randomazed trial
SSAC Strategic Screening Advisory Committee
UKLS UK Lung Screen
USPSTF US Preventive Services Task Force
VDT Volume doubling time
Introduction
Lung cancer causes 1.37 million deaths per year worldwide,
which represents 18 % of all cancer deaths [1]. Within the
European Union, lung cancer is the most frequently fatal can-
cer, leading to over 266,000 deaths yearly and accounting for
20.8 % of all cancer deaths [2]. Definitive surgery in the early
stages is the most effective treatment for lung cancer.
However, most patients are diagnosed at an advanced, and
thus non-curable, disease stage. Survival time decreases sig-
nificantly with progression of disease, with a 5-year survival
time declining from 50 % for clinical stage IA to 43 %, 36 %,
25%, 19%, 7% and 2% for stages IB, IIA, IIB, IIIA, IIIB and
IV, respectively [3]. Moreover, Shi et al. [4] reported a 5-year
survival rate of more than 80 % in 185 surgically treated
patients with peripheral small-sized lung cancers (2 cm or
less) after lobectomy and lymph node dissection. In particular,
the 5-year survival rate increased with smaller tumour size: 80
% in tumours 1.6–2.0 cm in diameter, 85 % in tumours 1.0–
1.5 cm in diameter and 100 % in tumours < 1.0 cm in diam-
eter, respectively. It is therefore crucial to detect lung cancer
early, before symptoms occur and while curable therapy is still
achievable.
During the past decade, several studies focused on the yield
of low dose computed tomography (LDCT)-based screening
for lung cancer. In total, roughly 100,000 high-risk individuals
were screened for lung cancer by LDCT. The largest
randomised trial, the US-based National Lung Screening
Trial (NLST), has shown a survival benefit for annual
LDCT, with a 20 % reduction of the lung cancer related mor-
tality, whereas the all-cause mortality decreased by 6 %.
However, there is still some debate associated with the appro-
priate algorithm with which to select the screening cohort, as
well as with how exactly the images should be read. The
second largest study, the European NEderlands-Leuvens
Screening ONderzoek (NELSON) trial, will be finalised by
the end of 2015 and will add insight, probably with a more
accurate screening algorithm and lower rate of false positivity,
as discussed by Shlomi et al. [5].
As the results of this large European study are pending and
the screening algorithms used in published studies have not
been universal, there are numerous issues that should be taken
into consideration before starting an LDCT screening pro-
gramme in Europe. This paper will review the current status
of lung cancer screening, and provide recommendations for
the standards and additional evidence required.
Status quo
Results of the current trials
The NLST is the first randomised, controlled lung cancer
screening trial in current and former smokers (> 30 pack-
years) aged between 55 and 74 years to show a significant
reduction in lung-cancer-specific mortality [6]. The computed
tomography (CT) screening arm of the trial involved 26,722
participants who received three yearly screening rounds of
LDCT. The control arm involved 26,732 participants who
received three yearly screening rounds using chest
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radiographs. After a follow-up period of approximately 6.5
years, participants in the CT screening arm were 20 % less
likely to die from lung cancer than those in the control arm. A
6 % reduction in overall mortality was also observed within
the 6.5-year period. In the CT screening arm, 356 participants
died from lung cancer, whereas the number in the correspond-
ing radiography arm was 443 [6]. In an additional evaluation
1 year later, these numbers had increased to 469 in the CTarm
and 552 in the radiography arm, which corresponds to a 15 %
reduction [7]. These results suggest that LDCT finds more
cancers, most of them being in stage IA (>50 %) and approx-
imately 10 % in stage IB [8]. Still, 43 % (469 out of 1089) of
those patients who developed lung cancer died of lung cancer.
The overall screening effort meant that 320 participants had to
be screened to prevent one lung cancer death within the 6.5-
year follow-up period [6].
The Dutch−Belgian NELSON trial is the largest European
randomised controlled trial with at-risk participants based on
age and smoking history randomly selected from population
registries. The first outcome data are expected in 2016. The
trial involves 7577 participants in the CT screening arm and
compares them to 7871 participants in the control arm [9].
Apart from a smoking cessation programme, no intervention
was offered in the control arm. Published results are available
from smaller randomised controlled trials from Denmark
(DLST) and Italy (Italung, DANTE and MILD). These trials
involved approximately 1000–2000 patients in each arm [10].
Published results suggest no advantage for lung cancer screen-
ing. In fact, DLST and MILD even found a trend towards
higher mortality in the yearly CT screening arms [11, 12].
Other current randomised controlled trials are the German
Lung Screening and Intervention (LUSI) trial and the UK
Lung Screening (UKLS) trial [13, 14].
Current recommendations
There is a wide range of acceptance of the general lung cancer
screening algorithm using LDCT across the globe; however,
different degrees of modification from the NLST algorithm
seem to be required (Table 1) [5].
From February 2012, the Lung Cancer Screening Panel of
the National Comprehensive Cancer Network (NCCN) in the
USA recommended annual LDCT screening of all high-risk
individuals between the age of 55 and 74 years, as defined in
the NLST [15]. However, the NCCN guidelines expanded the
NLST criteria based on non-randomised studies and observa-
tional data. Individuals 50 years of age or older with a tobacco
smoking history of 20 or more pack-years and one additional
risk factor should be screened annually. The suggested addi-
tional risk factors were history of cancer, history of lung dis-
ease [chronic obstructive pulmonary disease (COPD) or pul-
monary fibrosis], family history of lung cancer, radon expo-
sure and occupational exposure. The NCCN currently does
not advise screening of individuals at moderate and low risk
for lung cancer, or for individuals with exposure to second-
hand smoke [16].
A collaborative initiative of the American Cancer Society
[17], the American College of Chest Physicians (ACCP), the
American Society of Clinical Oncology [18], and the NCCN
published a review of LDCTscreening for lung cancer, togeth-
er with clinical practice guidelines, in May 2012 [10]. They
adopt the NLST eligibility criteria, but note that the duration
and frequency of screening remain undetermined [18]. In June
2012, guidelines for lung cancer screening were issued by the
American Association for Thoracic Surgery (AATS) [19],
expanding the criteria beyond the NLST. The AATS guide-
lines consider the amount of tobacco exposure and age to be
the most important risk factors, and therefore do not restrict
screening to patients who quit smoking in the previous 15
years. Since the risk of lung cancer does not decrease after
3 years of screening, the AATS recommends annual LDCT
screening for high-risk patients from age 55 to 79 years.
They consider that level 2 evidence is enough to advise
screening for smokers 50–79 years of age with a 20 pack-year
smoking history or other factors that produce a cumulative ≥ 5
% risk of developing lung cancer over the following 5 years.
Based on AATS consensus opinion (level 3 evidence), pa-
tients treated for primary bronchogenic carcinoma who have
completed 4 years of radiographic surveillance without evi-
dence for recurrence should also be screened. In January
2013, the American Cancer Society published guidelines that
recommend annual lung screening by LDCT based on the
NLST eligibility criteria until the age of 74 years [20]. In
May 2013, the ACCP published its third edition guidelines
of diagnosis and management of lung cancer, including a rec-
ommendation concerning lung cancer screening [21, 22].
Annual screening with LDCT for individuals who meet the
NLST eligibility criteria is recommended (grade 2B; weak
recommendation, moderate level of evidence).
In December 2013, the United States Preventive Services
Task Force (USPSTF) developed their recommendation state-
ment [23], which was published in March 2014 [24],
supporting LDCT lung cancer screening for healthy adults
between 55 and 80 years of age with a smoking history of
30 pack-years or more and who have smoked within the pre-
vious 15 years. The number of years needed for screening is
not specified, but screening should be discontinued once a
person has not smoked for 15 years or develops a health prob-
lem that substantially limits the life expectancy or the ability
or willingness to have curative lung surgery (grade B recom-
mendation). Under the Affordable Care Act [25], any proce-
dure that receives a grade B recommendation from the US
Preventive Services Task Force (USPSTF) has to be covered
by private insurers without co-payment. Most insurers in the
USA follow the recommendations of the task force, and pay
for those services. In April 2014, the US federal agency
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Center for Medicare and Medicaid services (CMS) advisory
panel voted against covering lung cancer screening [26]. Key
concerns were the high false-positive rate of CT screening,
indication creep outside of the intended screening population,
inability to assure quality scans with low radiation dose, and
consistent interpretation and diagnostic work-up in routine
practice. In February 2015, in contrast to the recommenda-
tions of the agency’s advisory board, Medicare announced
its decision to start covering annual lung cancer screening
once per year for long-time smokers at high risk for the disease
[27]. CMS experts require that screening candidates are be-
tween ages 55 and 77 years, have no signs or symptoms of
lung disease, have tobacco smoking history of at least 30
pack-years and are current smokers or ex-smokers who have
quit smoking within the previous 15 years. For the initial
screen, the beneficiary must receive a written order for
LDCT lung cancer screening obtained during a “lung cancer
screening counselling and shared decision-making visit” from
a physician, physician assistant, nurse practitioner or clinical
nurse specialist. CMS also gives details for that visit, radiolo-
gist eligibility criteria and imaging centre eligibility criteria
[27]. In Europe, there are no lung cancer screening recommen-
dations or reimbursed screening programmes so far.
Challenges
Pre-test probability
Tobacco smoking is a major risk factor for lung cancer, as
shown by many epidemiological studies. Other less important
risk factors are passive (second-hand) smoking, occupational
exposure, environmental exposure, residential radon expo-
sure, presence of COPD and family history of lung, head
and neck cancer. A meta-analysis of ten case−control studies
including 7609 cases and 10,431 controls shows an increase
of the relative risk of lung cancer in the European population
with active smoking (versus ex-smokers), with duration and
amount of smoking and the cumulative dose of pack-years
[28]. The recommendations for the NELSON trial are based
on data from the Cancer Prevention Study II (CPS II) [29].
According to this data, a smoking history of 30 years or more
in individuals older than 55 years and a consumption of at
least one pack of cigarettes a day correspond to a lung cancer
incidence of at least 300 per 100,000. The rate of lung cancer
diagnosed for those selected populations in recent randomised
trials by LDCT are summarised in Table 2.
More data from other cohorts are described in the system-
atic review published by Bach et al. [10]. The rate of lung
cancer diagnosed ranges between 0.8 and 2.2 % initially and
between 2.4 % and 4.7 % in 34−78 months of follow-up.
Those figures can be taken as the pre-test probability.
Overdiagnosis
The detection of small lesions confirmed to be malignant, but
which do not grow, spread, or cause death is referred to as
overdiagnosis. This includes patients who are destined to die
from another cause, e.g., comorbidity or an unexpected event,
in addition to slow growing/non-spreading cancers [10].
Overdiagnosis represents an important potential harm of
screening, since it incurs additional cost, anxiety and morbid-
ity associated with the cancer treatment. During earlier screen-
ing trials using chest radiographs in the Mayo and the
Czechoslovakian randomised trials, substantially more can-
cers (20 %) were detected in the screened than in the un-
screened group [30, 31]. Nearly all of the excess cancers de-
tected in the screened group in the Mayo clinical trial were
early stage cancers. However, the failure to detect early stage
cancers in the control group was without apparent ill effect:
the control group experienced no excess number of lung can-
cer deaths [30]. The results were generally confirmed by the
Czechoslovakian study. Both studies suggest that screening is
detecting “excess” lesions, which probably would not prog-
ress to advanced/lethal disease [30, 31]. The PLCO trial [17]
examined 155,000 subjects in the general population and
found 18 excess lung cancers in the chest radiography group
(compared with no chest radiography group) after 6 years of
follow-up (2 years after screening ended) and 76 lung cancers
after 13 years of follow-up. Data from the same trial, evaluat-
ing overdiagnosis among a high-risk population only, showed
a cumulative incidence of lung cancer of 606 per 100,000
person-years in the chest radiography group and 608 per
100,000 person-years in the usual care group after 6 years of
follow-up.
The overdiagnosis rate for LDCT screening cannot yet be
estimated [24]. The NLST data shows a persistent gap of
about 120 excess lung cancers in the LDCT versus the chest
radiography arm, but further follow-up is needed [32]. In both
groups, the percentage of stage IA and stage IB lung cancers
was high. Relative to the issue of overdiagnosis, fewer stage
IV cancers were detected in the LDCT group than in the chest
radiography group at the second and third screening rounds in
the DANTE trial, where 2472 subjects were screened with
chest radiography and sputum cytology at baseline and
randomised afterwards to yearly LDCT or clinical follow-up.
Lung cancer prevalence in the control chest radiography arm
was 0.67 % (n = 8) and 50 % of these patients had stage I
cancer, while the prevalence in the CT group was 2.19 % (n =
28) with 57 % stage I cancer, respectively. It has to be noted
that 13 of the 28 LDCT lung cancer cases already had abnor-
mal chest radiography findings at baseline [33].
Still, while most lung cancer prevention experts think lung
cancer screening leads to overdiagnosis, many clinicians be-
lieve it does not [34]. Death rates from lung cancer imply that
essentially all histological foci of lung cancer pose a threat to
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health, irrespective of their CT phenotype or how they are
discovered. In the NLST, the size of the nodule and whether
it is solid or sub-solid mattered. However, whether this ap-
pearance is linked to higher overdiagnosis probability remains
to be concluded. Based on the Pan-Canadian early Detection
of Lung Cancer Study (PanCan), McWilliams et al. [35] pre-
sented a model to predict a cancerous pulmonary nodule (ver-
sus benign). Predictors for cancer were older age, female sex,
family history of lung cancer, emphysema and larger nodule
size, location of the nodule in the upper lobe, part-solid nodule
type, lower nodule count and spiculation. Adopting such a
model may direct the clinicians in their follow-up
management.
Risk models
Risk models help to increase pre-test probability and reduce
overdiagnosis. They improve the patient selection in order to
define populations with higher pre-test probabilities: the
Liverpool Lung Project (LLP) risk prediction model is used
in the UKLS screening trial; the PLCO2012 (Prostate, Lung,
Colorectal, and Ovarian) randomised trial and the NLST trial.
The former two studies predict lung cancer detection, while
the latter predicts death by lung cancer (Table 3).
Recently, de Koning et al. [39] published a study estimat-
ing the harms and benefits of lung cancer screening for effi-
cient lung cancer screening policies. They used five separately
developed micro-simulation models calibrated to the two larg-
est randomised, controlled trials on lung cancer screening [17,
39]. Those models were independently developed at five in-
stitutions: Erasmus Medical Center (Rotterdam), Fred
Hutchinson Cancer Research Center (Seattle), Massachusetts
General Hospital (Boston), Stanford University (Stanford),
and University of Michigan (Ann Arbor). All account for the
individual’s age-specific, smoking-related risk for lung can-
cer, date and stage of lung cancer diagnosis, the corresponding
lung cancer mortality and the individual’s life expectancy in
the presence and absence of screening. The most advanta-
geous strategy identified is the annual screening from ages
55 through 80 years for ever-smokers with a smoking history
of at least 30 pack-years and ex-smokers with less than 15
years since quitting. That approach would lead to 50 % of
cases of cancer being detected at an early stage (stage I/II),
575 screening examinations per lung cancer death averted, a
14 % reduction in lung cancer mortality, 497 lung cancer
deaths averted, and 5250 life-years gained per the 100,000-
member cohort. Harms would include 67,550 false-positive
test results, 910 biopsies or surgeries for benign lesions, and
190 overdiagnosed cases of cancer (3.7 % of all cases of lung
cancer).
Thus far, there are no good risk predictors for nonsmokers
and no convincing data to recommend screening. Lung cancer
in never smokers is the seventh leading cause of cancer mor-
tality, and therefore is a significant cause of death worldwide.
The main risk factors include age, environmental tobacco ex-
posure, cooking fumes, inherited genetic susceptibility, occu-
pational and environmental exposure to carcinogens, hormon-
al factors, pre-existing lung disease and oncogenic viruses
[40]. Nonsmall cell lung cancer (NSCLC) in never smokers
is clinically characterised by an increased incidence in females
and a higher occurrence of adenocarcinoma in comparison to
NSCLC in ever smokers in both surgical patients and non-
resectable advanced stage patients [41]. Even though those
factors are known, there is no beneficial screening programme
for lung cancer among this population.
False positives and complications during work-up
With modern multidetector CT, pulmonary nodules are detect-
able at a size of less than 2 mm. Small nodules are extremely
common, but the vast majority of these nodules are benign.
Given this fact, the definition of a positive screening result
determines the number of false-positive results. On average,
about 25 % of the thoracic surgical procedures performed
Table 2 Selection criteria, number of enrolled individuals and the rate of diagnosed lung cancer of major randomised controlled trials
Study Selection criteria Patients screened n (follow-up) Lung cancer diagnosed at initial
screening (total in follow- up)
Age years Tobacco smoking (delay since weaning)
DLCST 50–70 ≥ 20 pack-years (0–9 years) 2052 (58 months) 0.8 % (3.4 %)
DANTE 60–74 ≥ 20 pack-years (0–9 years) 1276 (34 months) 2.2 % (4.7 %)
Only men
ITALUNG 55–69 ≥ 20 pack-years (active or former) 1406 (36 months) 1.5 % (2.8 %)
MILD ≥49 ≥ 20 pack-years (0–9 years) 1190* (120 months) 0.8 % (2.4 %)
1186† (53 months)
NELSON 50–75 ≥ 15 pack-years‡ (0–9 years) 7907 (60 months) 0.9 % (2.6 %)
NLST 55–74 ≥ 30 pack-years (0–15 years) 26722 (78 months) 1.1 % (2.4 %)
*Annual computed tomography; †Biannual computed tomography; ‡NELSON inclusion criteria: number of cigarettes smoked is ≥ 15 per day for 25
years OR ≥10 cigarettes per day for 30 years AND still smoking or having quit < 10 years ago.
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during the various randomised controlled lung cancer screen-
ing trials were done for benign nodules [21]. If there are fewer
false-positive nodules, there is less need for further workup
and lower risk of complications, especially from invasive di-
agnostic examinations including surgery.
The definition of a positive screening result differed sub-
stantially between the NLST and most European trials. The
NLST defined any non-calcified nodule with a maximum di-
ameter ≥ 4 mm as a positive screening result [6]. As a conse-
quence, the number of false-positive scans was high: 27 % of
scans in the first two screening rounds, of which 96 % were
false-positive. According to the NLST nodule management
algorithm, these suspicious nodules needed further
work-up: either a follow-up LDCT for nodules of 4–
10 mm, or a referral to a pulmonologist for nodules >
10 mm in maximum diameter [6].
The NELSON and some other European trials used a
threshold of approximately 10 mm diameter (50 mm3 vol-
ume) for a positive screening result, but also established an
indeterminate group of nodules measuring 5–10 mm in diam-
eter (50–500 mm3 volume) that required earlier follow-up
than the yearly screening interval [42]. Only if significant
growth (> 25 % volume change) was found, were these nod-
ules considered a positive screening result. By using this ap-
proach, the number of scans with positive screening results
was reduced from 27 % in the NLST to 2.7 % in the
NELSON, and the false-positives could be reduced substan-
tially from > 95 % in the NLST to approximately 50 % in the
NELSON [8, 43].
Recently, new criteria for the follow-up of pulmonary nod-
ules, such as LungRADS and LU-RADS, have been presented
in order to increase the positive predictive value in CT screen-
ing with minimum effect on sensitivity for the detection of
malignancy [44, 45].
The size of a nodule was measured in most screening trials,
like the NLST, as the largest diameter of a pulmonary nodule
[6]. This approach suffers from a substantial inter-reader and
intra-reader variability, which can be reduced by applying
volumetric techniques, as used in the NELSON and other
more recent trials. Non-actionable nodules were defined as
those with benign morphology (e.g., calcification), small size
(< 50 mm3), and lack of or very slow growth of the solid
Table 3 Risk prediction models used in different lung cancer screening trials
Model Risk factors included Period of prediction of lung
cancer diagnosis or death
Reference for algorithm
LLP (detection) Age 5 years Raji et al. [36]
Sex
Years of smoking
Family history of lung cancer by age of affected relatives
History of a previous cancer
History of pneumonia
History of exposure to asbestos




Chronic obstructive pulmonary disease
Personal history of cancer
Family history of lung cancer
Smoking status (current versus former)
Smoking intensity (average cigarettes/day)
Smoking duration
Smoking quit time





Years since smoking cessation
Presence of emphysema
First-degree relative with lung cancer
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component of a nodule with a volume doubling time (VDT) >
600 days. Indeterminate nodules were defined as nodules with
a volume of the solid component between 50 and 500 mm3,
sub-solid nodules with a diameter of the ground glass compo-
nent > 10 mm, or solid nodules with a VDT between 400 and
600 days. Actionable nodules were defined as solid compo-
nents > 500 mm3, more than 20 % growth in diameter of a
ground glass component, or VDT < 400 days of a solid com-
ponent [42]. Non-actionable, reportable nodules were kept on
regular (yearly) follow-up, indeterminate nodules were put on
a more rapid follow-up of 3–6 months, while actionable nod-
ules led to direct medical workup.
Increasing knowledge about the CT phenotypes of screen-
detected pulmonary nodules with different biologic behav-
iours will lead to a better estimation of their probability of
malignancy, and help to decrease the amount of additional
follow-up scans and workup examinations [46], e.g.,
perifissural nodules were demonstrated to have a high likeli-
hood of being benign [47, 48].
For the invasive diagnostic work-up of small nodules, the
value of white light fibrebronchoscopy is very limited [49],
but newer diagnostic endoscopic techniques, such as
endobronchial ultrasound-guided biopsy with mini probe or
electromagnetic navigation bronchoscopy, might be more
promising. For some peripheral nodules (> 1 cm), transthorac-
ic CT-guided biopsy or primary resection by video-assisted
thoracoscopic surgery for diagnostic and therapeutic reasons
may be recommended [50]. The risk of serious complications
(pneumothorax requiring drainage, cardiorespiratory compli-
cations during anaesthesia, infection or haemorrhage) not only
relates to the invasiveness of the diagnostic procedure itself,
but also to the patient’s functional status [51]. Subjects eligible
for LDCT screening will present themselves mostly with a
high comorbidity risk, due to COPD or chronic cardiovascular
disease [46, 52].
Adhering to a certified high quality radiology plan for
LDCT screening will minimise radiation exposure for screen-
ing participants. Further, the adherence to a pulmonary nodule
management plan based on nodule diameter, volume and
growth rate will help to increase safety for lung cancer screen-
ing participants, mostly by decreasing the total amount of
diagnostic investigations they will need to undergo in order
to determine the nature of their screen-detected lung nodules.
Moreover, a lower amount of false-positive lesions with a
decreased number of additional diagnostic investigations
may finally help to decrease participant’s anxiety and psycho-
logical stress during lung cancer screening [53].
Radiation exposure
The vast majority of lung cancer screening trials were de-
signed more than a decade ago. The LDCT protocols were
simply achieved by reducing the fixed tube load of diagnostic
CT from typically 100–300 mAs to 10–40 mAs. A CT dose
index (CTDIvol) of 2–3 mGy was used as a target for NLST
[54, 55]. Similar values were used in the NELSON and the
various other European trials. The resulting effective dose is
roughly 40 % of these values for males and 50 % for females,
resulting in 1–1.3 mSv for a CTDIvol of 2.5 mGy. The organ
dose (mSv) to the lung or to the breast can be roughly esti-
mated using 1.5×CTDIvol. Precise numbers vary depending
on scanner type, and in particular on the pre-filtering of the X-
ray spectrum.
With recent improvements in detector technology, automat-
ed exposure control techniques and iterative image reconstruc-
tion, a further substantial decrease in radiation exposure of 80
% to a level around 0.2 mSv is possible without impairing
image quality [56]. However, radiation exposure will always
have to be higher in obese individuals than in normal weight
individuals because of the difference in X-ray absorption.
Excessive reduction of radiation dose will lead to image qual-
ity degradation with either high image noise or loss of image
details, which will especially affect sub-solid lesions. These
are the limiting factors for further dose reduction.
Radiation risk in the age range of 40 to 60 years is mainly
determined by the organ dose to the lungs. Apart from the
breast in premenopausal women, other organs have a much
lower contribution to excess cancer risk [57]. Radiation expo-
sure and smoking appear to have an additive effect on cancer
risk [58]. This means that the excess risk for developing
radiation-induced lung cancer may be twice as high in
smokers as in never-smokers [59].
Given an effective dose of 1.3 mSv for women and 1.0
mSv for men, the excess lifetime cancer risk was estimated
to be 0.02% inmale smokers and 0.05% in female smokers if
three yearly screening rounds were performed [60]. Risks did
not change whether the starting age for screening was 30, 40
or 50 years. This implies that radiation risk becomes important
only if the pre-test risk for lung cancer is small. Given a base-
line cancer risk of 0.8–2.2% in the various screening trials, the
risk−benefit ratio is very favourable. Even if the number of
screening examinations increases from three to 24, the excess
lifetime cancer risk induced by radiation remains below the
baseline cancer risk, but it increases with age [38].
Radiation risk grows strongly if follow-up scans are per-
formed using standard clinical protocols (old equipment 4–18
mSv, new equipment 2–4 mSv [61]) instead of screening with
LDCT settings (new equipment 0.2 mSv [56]). For this rea-
son, the work-ups of screen-detected nodules should remain
within the screening programme as long as possible [62].
Cost effectiveness
The cost-effectiveness of the screening intervention is one of
the major considerations for those who are responsible for
screening guidelines, practice measures and insurance
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coverage [63]. Varying results on the cost-effectiveness of
lung cancer screening have been reported [64–67]. In their
recent publication, the NLST reports reasonable cost-
effectiveness of LDCT screening of lung cancer [68]. LDCT
screening as performed in the NLST trial costs $81,000 per
quality-adjusted life year (QALY) gained (95 % CI $52,000–
186,000). Screening trials that cost less than $100,000 per
QALY are considered cost-effective. Incremental cost effec-
tiveness ratio (ICER) is the ratio of the change in costs to
incremental benefits of a therapeutic intervention or treatment
[69]. The NLST ICER was $52,000 (95 % CI $34,000–106,
000). However, the ICER results of the NLST were highly
sensitive to base-case assumptions. For example, if the reduc-
tion in mortality from causes other than lung cancer was in-
cluded in the calculation, the QALY fell to $54,000. QALY
increased to more than $100,000 when the cost of future care
was increased. Moreover, estimated cost-effectiveness varied
in the subgroup analysis. Screening with LDCT was much
more cost-effective in women than in men and among the
groups with a higher risk of lung cancer. Whether screening
performed in different countries in Europe will be cost-
effective depends on exactly how the screening will become
implemented [68], and onwhich respective cost structures and
reimbursement policies will be used.
Expectation management
Expectationmanagement is crucial for a successful CTscreen-
ing programme. It is important for three main reasons: 1)
giving participants the ability to understand the benefits and
potential harms, 2) reducing anxiety in case a nodule is found
and 3) reducing litigation and its chances for success.
Screening is very likely to reduce a participant’s risk of dying
from lung cancer. However, a substantial group of participants
will still die from lung cancer. Most cancers found will be in a
treatable stage (60–80 % stage I) – but not all [8, 70]. Some
cancers may grow so slowly that they will not be life-limiting
and treating them may be unnecessary (overdiagnosis) [39].
Screening is known to miss nodules present on LDCT [71].
The annual screening programme will pick up nodules missed
on earlier scans, which reduces the risk of missed nodules
developing into untreatable cancer. As small nodules are ex-
tremely common, it is very likely that a nodule will be found.
LDCT is not optimally suited for the detection and diagnosis
of many other chest diseases. However, incidental findings
leading to unnecessary workup, costs and complications
may occur.
Information given to participants, clinicians not involved in
screening and the public should be clearly understandable.
Informed consent is important because of the dangers of un-
detected cancers, overdiagnosis or complications due to work-
up or treatment of screen-detected lesions. The participants
should be aware of the incidental finding policy of the screen-
ing programme.
Broaden the scope
CT-based screening can provide a more global approach of a
smoker’s lung and associated comorbidities, which are associ-
ated with poor health status and prognosis [72, 73]. Regarding
smoker’s lung features, namely airway disease and emphyse-
ma, they can be easily depicted and categorised according to
the proposed CT phenotypes [74]. In addition, it is also possi-
ble to detect interstitial lung abnormalities in cigarette smokers,
as recently observed in 8 % of the COPDGene cohort (194 out
of 2416) [75]. While such abnormalities are visually assessed,
recent approaches favour automated extraction and quantifica-
tion of morphological changes in order to refine COPD phe-
notyping [76] and help predict clinical impairment [77].
Smokers have a highly increased risk for the development
of cardiovascular diseases, which also coexist with COPD
[72]. Since lung cancer screening examinations use non-
contrast and non-ECG-gated acquisitions, precise analysis of
mural changes at the level of coronary arteries, as well as
thoracic aorta, remains beyond the scope of such examina-
tions. However, several studies have documented the feasibil-
ity of an imaging approach combining lung cancer and quan-
tification of coronary artery calcium in a single chest CTstudy
[78, 79]. Quantification of coronary and aortic calcium vol-
umes in lung cancer screening CT images has recently been
shown to help predict cardiovascular risk. Such an approach
might prove useful in the reduction of cardiovascular morbid-
ity and mortality, and may enhance the cost-effectiveness of
CT-based screening in heavy smokers [80]. Other key targets
such as calcifications at the level of heart valves and/or supra-
aortic arteries could also be included. Osteoporosis is also
increasingly recognised as a major comorbidity that can be
picked up on LDCT of the chest.
The specificity of a screening programme might also be
increased by including non-imaging, non-invasive biomarkers
to allow a better discrimination between benign versus malig-
nant conditions. Examination of serum and plasma bio-
markers shows some evidence supporting the rationale of
using these biomarkers for risk stratification of screen-
detected lung nodules [81–83]. However, there are only few
biomarkers that could be implemented immediately. We en-
courage the community to further investigate in this area and
define it as an urgent unmet need in the field of lung cancer.
Suggestions
The European Society of Radiology and the European
Respiratory Society are recommending lung cancer screening
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in comprehensive, quality-assured programmes within a clin-
ical trial or in routine clinical practice at certified multidisci-
plinary medical centres. Based on the results and experience
of completed and on-going lung cancer screening activities,
we suggest the following minimum requirements for the im-
plementation of lung cancer screening:
& Accredited medical centres with multidisciplinary exper-
tise and access to trained professionals, including, as a
minimum, radiologists, pulmonologists, oncologists, pa-
thologists and chest surgeons.
& Strong smoking cessation programme and experienced
staff providing effective cessation and long-term absti-
nence advice.
& Longitudinal comprehensive screening programme
throughout the age interval of eligibility, covering
the complete protocol, including work-up, follow-up
and potential re-entry, also offering an appropriate
expectation management. Single-round screening is
discouraged.
& Inclusion criteria: age between 55 and 80 years, tobacco
smoking history of at least 30 pack-years, and current
smoker or ex-smoker who has quit smoking within the
last 15 years.
& Exclusion criteria: comorbidities precluding curative ther-
apy and lack of consent to undergo curative therapy.
& Standardised operating procedures for image acquisition,
nodule evaluation, positive screening results and their
management, monitoring of false-positive results and rate
of iatrogenic complications, and appropriate follow-up.
& Computer-assisted nodule evaluation and documentation.
Identical measurement software is required for the follow-
up. Volumetric measurements are preferred over diameter
measurements.
& Multidetector LDCT with at least 16 detector rows
providing isotropic high spatial resolution (slice
thickness of about 1 mm with an increment of 0.7
mm) and an effective dose between 1 mSv for nor-
mal sized individuals and not more than 3 mSv for
obese individuals.
& Collection and submission of lung cancer screening data
to a lung cancer screening registry. The set-up of a
European lung cancer screening registry including
biobank and image bank is encouraged.
We also recommend the implementation of the following
measures in order to increase quality, outcome and cost-
effectiveness of lung cancer screening:
& To increase the pre-test probability by using a risk model
and considering additional risk factors.
& To reduce the effective radiation dose to less than 1 mSv
per CT examination for all participants.
& To use volumetric measurements for the assessment of
growth rate (tumour doubling time) in order to reduce
the rate of false-positives.
& To use computer-assisted systems for automated detec-
tion, optimised measurements and follow-up, providing
structured reports on nodule volume, localisation, pheno-
type and standard operating procedure-based suggestions
for further management plan.
& To adapt screening intervals based on refined risk models.
& To include additional CT findings such as COPD and
vascular calcification.
& To include and study biomarkers to better define screening
subgroups and refine nodule management.
Conclusion
Lung cancer is a devastating disease with poor survival once
the disease is advanced. As the main risk factor for lung cancer
is smoking, there is an urgent need to advocate against
smoking and encourage cessation. There are accumulated data
supporting the survival benefit for screening of individuals at
high risk for early detection of lung cancer using LDCT.
Based on the available evidence, we have summarised the
key elements necessary for a comprehensive lung cancer
screening programme in Europe, including minimum require-
ments and recommended refinements. These should be adjust-
ed to the national infrastructure and healthcare system in order
to exactly define eligibility using a risk model, nodule man-
agement and quality assurance plan. The establishment of a
central registry, including a biobank and an image bank, pref-
erably on a European level, is strongly encouraged.
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